Infermedica 2025: A year in review

With the launch of our first next-generation products under our new neurosymbolic AI concept, 2025 really stood out as the year we entered fully into Infermedica 2.0.

It was exciting from many standpoints. From the launch of new products to obtaining MDR Class IIb certification for our Medical Guidance Platform, from proving our value and impact via peer-reviewed research to the fantastic stage presence that the team had across multiple fields of expertise, there were so many reasons to be proud of Infermedica and the team behind it.

And that’s not to mention the fantastic healthcare organizations around the world that started or continued to collaborate with us to bring us one step closer to our ultimate goal: to make healthcare accessible, affordable, and convenient for all.

I’d like to share a few highlights of the past 12 months.

Milestones of 2025

Let’s kick off the celebrations by mentioning two big milestones that reflect over a decade of trust, commitment, and collaboration. Firstly, we completed our 25 millionth health checkup! That’s 25 million times that Infermedica’s solutions have been used to open up timely access to healthcare services.

In addition, I want to give a huge shout-out to our amazing team of doctors. In the summer, we surpassed 150,000 hours of doctors' work, which goes into ensuring that our world-class Medical Knowledge Base is complete, up-to-date, and accurate. A personal thank you to each and every one of the doctors we’ve had on our team.

The Agentic AI journey: Launching Neurosymbolic AI for triage

Back in April, we launched Conversational Triage—the first real-world application of our neurosymbolic paradigm. Anchored in medical knowledge and guidelines, this intelligent agentic AI tool reasons, validates, and explains its logic. In a world of AI uncertainty, hallucinations, and black boxes, we are incredibly proud to set a new standard for responsible healthcare AI. One in which every interaction produces medically sound guidance, transparent logic, and clear, actionable next steps.

What’s next for Conversational Triage in 2026?

The short answer: Medical device certification and integration with multi-agent systems.

We’re already in the process of obtaining MDR certification for Conversational Triage, a step that we hope to see completed in 2026. By certifying Conversational Triage under MDR guidelines, we are reaffirming our commitment to clinical safety, regulatory compliance, and transparency, thereby giving our clients confidence that the solution meets stringent EU standards.

The team is simultaneously working on ensuring smooth integration with multi-agent systems (for example, Agent-to-Agent systems) to allow Conversational Triage to coordinate seamlessly with other AI tools—collaborating with scheduling systems, EHR and clinical documentation platforms, practice-management software, etc. Agent-to-Agent integration will also open possibilities for adding a conversational voice layer, enabling natural spoken interactions and making Conversational Triage accessible across voice-first and multimodal care experiences.

It’s an exciting time for Conversational Triage—watch this space!

MDR Class IIb certification

This year also saw big movement for our Medical Guidance Platform, which includes modules Triage, Intake, and Follow-up.

The Medical Guidance Platform achieved MDR Class IIb certification!

This is one of the highest possible levels of compliance for Software as a Medical Device (SaMD) in Europe. Class IIb is reserved for solutions that directly impact patient care—where accurate, reliable guidance is vital to avoid death, long-term disability, or serious health deterioration.

Achieving Class IIb certification acts as further proof that Infermedica is leading the way when it comes to delivering medical software that patients, physicians, and healthcare organizations can rely on.

Accuracy and impact

This year, we continued our research into the quality, accuracy, safety, and value of our AI-driven healthcare solutions. We published 6 peer-reviewed papers and appeared in 2 more papers published by our partners.

Relationships that sparkle: Partners and clients

As well as continued collaboration with respected partners and clients that we’ve worked with for many years, we’ve also had the pleasure of beginning new relationships and meeting with more teams to expand the reach of AI-driven healthcare solutions to more regions and new markets.

To keep it short, here I share just two of the collaborations we’re proud of this year.

In Germany, 2025 saw the introduction of Annex 31c of the BMVA, which put in place new regulations for telemedicine providers. We’re proud to support German telemedicine companies through this change, not only meeting regulatory expectations but working with teams to ensure that the implementation of new technology drives added value to end users. Read about our collaboration with TeleClinic.

In Australia, our continued collaboration with Healthdirect Australia has generated amazing results. Infermedica’s solutions have added value to Healthdirect Australia’s already impressive care offerings through two channels: the nurse advice line and the self-triage symptom checker. These channels open up access to healthcare for 26 million Australian citizens and have already seen the following results:

• 71% increase in self-assessment completion rates

• 9% improvement in triage accuracy

• 46% reduction in overtriage compared to the legacy system

#InferOnStage

This year, the team traveled to the United States, Germany, Spain, Poland, the Netherlands, and the United Kingdom to attend major healthcare conferences. We learnt a lot from various panel discussions, presentations, and conversations with truly inspiring people within the health tech space.

I’m also proud to see the Infermedica team was invited to join so many on-stage discussions, from AI challenges and safety to the value of healthtech solutions for patients and even the depths of software engineering. Our commercial, medical, and engineering teams shared their knowledge and experience in their fields. Here are a few highlights from events this year.

Recognition and gratitude

Finally, I’d like to congratulate the whole Infermedica team for their outstanding hard work and dedication. I’m proud to work alongside a team of dedicated professionals who each have a real drive to produce the best in their individual fields of expertise.

Our engineers, medical content specialists, translators, and product and commercial teams work with passion for our mission: to make healthcare more accessible, affordable, and convenient for all.

This dedication to excellence is also reflected in a few awards that we picked up this year. Congrats to the team and thanks to all the award organizations for the recognition in the following categories.

Winner—Innovation in Self-Care: Awarded to our Symptomate Chatbot, which is based on Conversational Triage.

Winner—Digital Health Awards Spring 2025: Clinical Decision Support Tools: Awarded to our Symptom Checker & Virtual Triage solution.

Winner—Global Tech Awards for Medical Technology: Award to Infermedica for our solutions and mission to make healthcare more accessible through cutting-edge AI.

Winner—FeedSpot Top AI in Healthcare Blog: Awarded to our healthcare blog page, where we share information on market trends, product updates, and partner implementations.

Looking to 2026

From a product perspective, as I mentioned earlier, our primary focus for 2026 will be on our Agentic AI solutions—especially focusing on the MDR certification of Conversational Triage and giving organizations the option of adding voice capabilities.

That being said, with the Medical Guidance Platform already MDR Class IIb certified, this has sparked many conversations within the public health and government sector—a sector we are very familiar with, considering our continued success with Healthdirect Australia. I’m personally looking forward to more discussions about bringing accessible healthcare solutions to population-scale markets.

But now it’s the time of year to take a step back and reflect on 2025. There have been many highs and many challenges. From both a professional and personal standpoint, I believe it’s important to take this moment of the year to consider all that has happened, to celebrate successes, and also take lessons from the hurdles that we met.

With that, I’d like to say a final thank you for your continued support. To our partners, clients, investors, Symptomate users, and everyone in the Infermedica team—Thank you!

Have a wonderful holiday season and a great new year!

BL/EN/2026/01/07/1